| Market Size in 2024 | Market Forecast in 2034 | CAGR (in %) | Base Year |
|---|---|---|---|
| USD 17.83 Billion | USD 53.68 Billion | 11.8% | 2024 |
FrequentlyAsked Questions
The europe precision medicine market is expected to grow due to growing prevalence of chronic diseases, increasing demand for targeted therapies, rising healthcare investments, and supportive government initiatives for personalized medicine.
According to a study, the europe precision medicine market size was worth around USD 17.83 Billion in 2024 and is expected to reach USD 53.68 Billion by 2034.
The europe precision medicine market is expected to grow at a CAGR of 11.8% during the forecast period.
Europe is expected to dominate the europe precision medicine market over the forecast period.
Leading players in the europe precision medicine market include Eli Lilly & Co., Pfizer, Dong-A Pharmaceutical Co. Ltd, Bayer AG, Meda Pharmaceuticals, Vivus Inc., and Apricus Biosciences, among others.
The report explores crucial aspects of the europe precision medicine market, including a detailed discussion of existing growth factors and restraints, while also examining future growth opportunities and challenges that impact the market.
HappyClients